MedTrace Logo

Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy

NCT00653848 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 378

Last updated 2021-03-25

No results posted yet for this study

Summary

As docetaxel is proven to be effective in late stages of prostate cancer with a large tumour burden it should be effective in primarily treated intermediate and high risk prostate cancer as an adjuvant treatment after radiotherapy to prevent early relapse. This will therefore be tested in a randomised phase III trial where patients will be randomized either to docetaxel or surveillance

Conditions

Interventions

DRUG

docetaxel

docetaxel 75 mg/square meter i.v. every third week, six cycles

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Scandinavian Prostate Cancer Group

    lead NETWORK

Principal Investigators

  • Pirkko-Liisa i Kellokumpu-Lehtinen, Prof · Tampere University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2023-08-30
Completion
2023-08-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00653848 on ClinicalTrials.gov